Consequently, they suggest that targeting the c-Met/FRA1/Hey1 cascade mediated by CAF-derived HGF could serve as a potential therapeutic approach for hepatocellular carcinoma (HCC). The gene discussed is FOSL1; the disease is hepatocellular carcinoma.